Invasive fungal infections during the neonatal period: Diagnosis, treatment and prophylaxis

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 2, 2012, Pages 193-205

  Tezer, Hasan ^a   Canpolat, Fuat Emre ^b   Dilmen, Uǧur ^b  

^a GAZI UNIVERSITY   (Turkey)

^b Neonatal Intensive Care Unit   (Turkey)

Author keywords

Diagnosis; Invasive fungal infection; Neonates; Prevention; Treatment

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; GALACTOMANNAN; ITRACONAZOLE; MANNAN; MICAFUNGIN; NYSTATIN; PLACEBO; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC THERAPY; ASPERGILLOSIS; ASPERGILLUS; BLOOD CULTURE; CANDIDA; CENTRAL VENOUS CATHETER; EARLY DIAGNOSIS; FUNGAL COLONIZATION; HUMAN; HYPOKALEMIA; IMMUNE DEFICIENCY; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; NEPHROTOXICITY; NEWBORN PERIOD; PARENTERAL NUTRITION; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMIC MYCOSIS; THROMBOPHLEBITIS; VERY LOW BIRTH WEIGHT; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; CATHETERS, INDWELLING; CROSS INFECTION; HUMANS; INFANT, NEWBORN; MYCOSES;

EID: 84855884747     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.647685     Document Type: Review

References (119)

1. Brecht M, Clerihew L, McGuire W. Prevention and treatment of invasive fungal infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2009;94:F65-9
2. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995 -2004. Pediatrics 2006;117:1680-7 (Pubitemid 46071397)
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91 (Pubitemid 34833012)
4. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92 (Pubitemid 46050523)
5. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birthweight infants with neonatal infection. JAMA 2004;292:2357-65 (Pubitemid 39491920)
6. Manzoni P, Maestri A, Leonessa M, et al. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J Perinatol 2006;26:23-30 (Pubitemid 43135251)
7. Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis 2000;19:822-7
8. Noyola DE, Fernandez M, Moylett EH, et al. Opthamologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001;32:1018-23 (Pubitemid 32299636)
9. Clerihew L, Lamagni TL, Brocklehurst P, et al. Invasive fungal infection in very low birth weight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed 2006;91:F188-92
10. Filioti I, Iosifidis E, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin Pharmacother 2008;9:3179-96
11. Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007;26:723-7 (Pubitemid 47424643)
12. Manzoni P, Farina D, Leonessa M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006;118:2359-64 (Pubitemid 46397574)
13. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000;19:319-24 (Pubitemid 30213071)
14. Lamagni TL, Evans BG, Shigematsu M, et al. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990 - 9). Epidemiol Infect 2001;126:397-414 (Pubitemid 32640703)
15. Bendel CM. Candidiasis. In: Remington JS, Klein JO, Wilson CB, Baker CJ, editors. Infectious diseases of the fetus and newborn infant. 6th edition. Elsevier Saunders; Philadelphia: 2006. p. 1107-28
16. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-43 (Pubitemid 37100802)
17. Benjamin DK Jr, Stoll BJ. Infection in late preterm infants. Clin Perinatol 2006;33:871-82 (Pubitemid 44828736)
18. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17 (Pubitemid 39050477)
19. Dornbusch HJ, Manzoni P, Roilides E, et al. Invasive fungal infections in children. Pediatr Infect Dis J 2009;28:734-7
20. Lopez Sastre JB, Coto Cotallo GD, Fernandez CB. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20:153-63 (Pubitemid 36682311)
21. Kaufman DA, Gurka MJ, Hazen KC, et al. Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J 2006;25:733-7 (Pubitemid 44162132)
22. Manzoni P, Farina D, Galletto P, et al. Type and number of sites colonized by fungi and risk of progression to invasive fungal infection in preterm neonates in neonatal intensive care unit. J Perinat Med 2007;35:220-6 (Pubitemid 46700985)
23. Kicklighter SD, Springer SC, Cox T, et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001;107:293-8 (Pubitemid 32121244)
24. Bendel CM. Colonization and epithelial adhesion in the pathogenesis of neonatal candidiasis. Semin Perinatol 2003;27:357-64 (Pubitemid 37363188)
25. Chiu NC, Chung YF, Huang FY. Pediatric nosocomial fungal infections. Southeast Asian J Trop Med Public Health 1997;28:191-5
26. Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2007;4:CD003850
27. Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fl uconazole prophylaxis. J Pediatr 2005;147:135-41 (Pubitemid 41207822)
28. Steinbach WJ. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J 2005;24:358-64 (Pubitemid 40525345)
29. Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr Med Res Opin 2010;26:1779-87
30. Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 1998;27:437-52
31. Robertson AF, Joshi VV, Ellison DA, et al. Zygomycosis in neonates. Pediatr Infect Dis J 1997;16:812-15 (Pubitemid 27364796)
32. Kaufman D. Fungal infection in the very low birthweight infant. Curr Opin Infect Dis 2004;17:253-9 (Pubitemid 38703856)
33. Roilides E, Zaoutis TE, Katragkou A, et al. Zygomycosis in neonates: an uncommon but life-threatening infection. Am J Perinatol 2009;26:565-73
34. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of Intravascular catheter-related infections. Clin Infect Dis 2002;35:1281-307 (Pubitemid 35448956)
35. Menon G. Neonatal long lines. Arch Dis Child Fetal Neonatal Ed 2003;88:260-2
36. Lopez LFC. Benefits of the epicutaneous catheter in the newborn infant. Rev Cubana Enferm 2004;20:1-10
37. Aggaewal R, Downe L. Use of percutaneos Silastic central venous catheter in management of newborn infants. Indian Pediatr 2001;38:889-92 (Pubitemid 33662372)
38. Pessoa-Silva CL, Miyasaki CH, de Almeida MF, et al. Neonatal late-onset bloodstream infection: attributable mortality, excess of length of stay and risk factors. Eur J Epidemiol 2001;17:715-20 (Pubitemid 34602337)
39. Ramasethu J. Complications of vascular catheters in the neonatal intensive care unit. Clin Perinatol 2008;35:199-222 (Pubitemid 351232005)
40. Powers RJ, Wirtschafter DW. Decreasing central line associated bloodstream infection in neonatal intensive care. Clin Perinatol 2010;37:247-72
41. Geffers C, Gastmeier A, Schwab F, et al. Use of central venous catheter and peripheral venous catheter as risk factors for nosocomial bloodstream infection in very-low-birth-weight infants. Infect Control Hosp Epidemiol 2010;31:395-401
42. Cronin WA, Germanson TP, Donowitz LG. Intravascular catheter colonization and related bloodstream infection in critically ill neonates. Infect Control Hosp Epidemiol 1990;11:301-8
43. Parellada JA, Moise AA, Hegemier S, Gest AL. Percutaneous central catheters and peripheral intravenous catheters have similar infection rates in very low birth weight infants. J Perinatol 1999;19:251-4
44. Krediet TG, Mascini EM, Rooij E, et al. Molecular epidemiology of coagulase-negative staphylococci causing sepsis in a neonatal intensive care unit over an 11 year period. J Clin Microbiol 2004;42:992-5 (Pubitemid 38332815)
45. Sengupta A, Lehmann C, Diener-West M, et al. Catheter duration and risk of CLA-BSI in neonates with PICCs. Pediatrics 2010;125:648-53
46. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006;20:711-27 (Pubitemid 44375116)
47. Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993;17:103-9 (Pubitemid 23294544)
48. Downey LC, Smith PB, Benjamin DK, et al. Recent advances in the detection of neonatal candidiasis. Curr Fungal Infect Rep 2010;4:17-22
49. Schelonka RL, Moser SA. Time to positive culture results in neonatal Candida septicemia. J Pediatr 2003;142:564-5 (Pubitemid 36623569)
50. Terlecka JA, du Cros PA, Orla Morrissey C, et al. Rapid differentiation of C. albicans from non-albicans species by germ tube test directly from BactAlert blood culture bottles. Mycoses 2007;50:48-51 (Pubitemid 46046419)
51. Arendrup MC, Fisher BT, Zaoutis TE. Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues. Clin Microbiol Infect 2009;15:613-24
52. Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol 2005;43:3925-31 (Pubitemid 41129682)
53. Mennink-Kersten MA, Klont RR, Warris A, et al. Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet 2004;363:325-7 (Pubitemid 38142420)
54. Siemann M, Koch-Dorfler M. The Platelia Aspergillus ELISA in diagnosis of invasive pulmonary aspergillosis (IPA). Mycoses 2001;44:26672
55. Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003;349:2366-7 (Pubitemid 37509754)
56. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205 (Pubitemid 38971490)
57. Oliveri S, Trovato L, Betta P, et al. Experience with the Platelia Candida ELISA for the diagnosis of invasive candidosis in neonatal patients. Clin Microbiol Infect 2008;14:391-3 (Pubitemid 351356534)
58. Farmaki E, Evdoridou J, Pouliou T, et al. Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol 2007;24:127-35 (Pubitemid 46363830)
59. Fujita SI, Senda Y, Nakaguchi S, et al. Multiplex PCR using internal transcribed spacer 1 and 2 regions for rapid detection and identification of yeast strains. J Clin Microbiol 2001;39:3617-22 (Pubitemid 32954511)
60. Martin C, Roberts D, van der Weide M, et al. Development of a PCR-based line probe assay for identification of fungal pathogens. J Clin Microbiol 2000;38:3735-42
61. Tirodker UH, Nataro JP, Smith S, et al. Detection of fungemia by polymerase chain reaction in critically ill neonates and children. J Perinatol 2003;23:117-22 (Pubitemid 36511738)
62. Thompson GR III, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med 2009;30:203-15
63. Chapman RL. Prevention and treatment of Candida infections in neonates. Semin Perinatol 2007;31:39-46 (Pubitemid 46273662)
64. Almirante B, Rodriguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007;9:311-21 (Pubitemid 47557113)
65. Lass-Florl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev Anti Infect Ther 2010;8:127-35
66. Das S, Shivaprakash MR, Chakrabarti A. New antifungal agents in pediatric practice. Indian Pediatr 2009;46:225-31
67. Bliss JM, Wellington M, Gigliotti F. Antifungal pharmacotherapy for neonatal candidiasis. Semin Perinatol 2003;27:365-74 (Pubitemid 37363189)
68. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin b and 5-fluorocytosine in neonates. J Pediatr 1990;116:791-7 (Pubitemid 20162837)
69. Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin b preparations. J Antimicrob Chemother 2003;52:663-7 (Pubitemid 37258429)
70. Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 2001;84:131-3
71. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17:146-8 (Pubitemid 28096014)
72. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89 (Pubitemid 38113025)
73. Pappas PG, Kauffman CA, Andes D, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
74. Smith PB, Steinbach WJ, Benjamin DK Jr. Neonatal candidiasis. Infect Dis Clin North Am 2005;19:603-15 (Pubitemid 41133531)
75. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005;52:895-915 (Pubitemid 40733599)
76. Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988;157:178-80 (Pubitemid 18037468)
77. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am 2006;20:663-78 (Pubitemid 44389928)
78. Kohli V, Taneja V, Sachdev P, et al. Voriconazole in newborns. Indian Pediatr 2008;45:236-8 (Pubitemid 351457466)
79. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer 2010;54:1050-2
80. Garnock-Jones KP, Keam SJ. Caspofungin: in pediatric patients with fungal infections. Paediatr Drugs 2009;11:259-69
81. Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-7 (Pubitemid 43019041)
82. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-45 (Pubitemid 41552583)
83. Fisher BT, Zaoutis T. Caspofungin for the treatment of pediatric fungal infections. Pediatr Infect Dis J 2008;27:1099-102
84. Saez-Llorens X, Macias M, Mniya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infanls less than 3 months of age. Antimicrob Agents Chemother 2009;53:869-75
85. Carter NJ, Keating GM. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs 2009;11:271-91
86. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-15 (Pubitemid 44900673)
87. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates. J Infect Dis 2008;197:163-71 (Pubitemid 351263481)
88. Kawaguchi C, Arai I, Yasuhara H, et al. Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr Int 2009;51:220-4
89. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010;87:93-9
90. Friedman S, Richardson SE, Jacobs SE, et al. Systemic candida infection in extremely low birth weight infants: short term morbidity and long-term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19:499-504 (Pubitemid 30409474)
91. Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003;52:663-7 (Pubitemid 37258429)
92. Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996;15:1107-12 (Pubitemid 27014703)
93. Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003;22:603-7 (Pubitemid 37363539)
94. Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008;52:4043-9
95. Cohen-Wolkowiez M, Moran C, Benjamin DK Jr. Pediatric antifungal agents. Curr Opin Infect Dis 2009;22:553-8
96. Frattarelli DA, Reed MD, Giacoia GP, et al. Antifungals in systemic neonatal candidiasis. Drugs 2004;64:949-68 (Pubitemid 38608474)
97. Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 1989;8:99-104 (Pubitemid 19067084)
98. Smolinski KN, Shah SS, Honig PJ, et al. Neonatal cutaneous fungal infections. Curr Opin Pediatr 2005;17:486-93 (Pubitemid 41104065)
99. Kwon DS, Mylonakis E. Posaconazole: a new broadspectrum antifungal agent. Expert Opin Pharmacother 2007;8:1167-78 (Pubitemid 46937838)
100. Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first three months of life. Clin Infect Dis 1998;27:437-52
101. Morales-Molina JA, Mateu-de Antonio J, Grau S, et al. Is routine fluconazole prophylaxis necessary in preterm infants? Pharm World Sci 2006;28:163-4 (Pubitemid 44584050)
102. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660-6 (Pubitemid 33126821)
103. Aziz M, Patel AL, Losavio J, et al. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr Infect Dis J 2010;29:352-6
104. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483-95 (Pubitemid 46919774)
105. Bertini G, Perugi S, Dani C, et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005;147:162-5 (Pubitemid 41207827)
106. Healy CM, Campbell JR, Zaccaria E, et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008;121:703-10
107. Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009;28:717-23
108. Allen U, Richardson S, McGuire W, et al. Pediatric antifungal therapy. Part II: neonatal infections. Minerva Pediatr 2010;62:71-8
109. Candidiasis. In: Pickering L, Kimberlin DW, Baker CJ, Long SS, editors. Red Book: 2009 Report of the Committee on Infectious Diseases. American Academy of Pediatrics; Elk Grove Village, IL: 2009. p. 245-9
110. Reed BN, Caudle KE, Rogers PD. Fluconazole prophylaxis in high-risk neonates. Ann Pharmacother 2010;44:178-84
111. Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008;27:731-7
112. Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of < 1000 grams birth weight. J Pediatr 2005;147:172-9 (Pubitemid 41207829)
113. McCrossan BA, McHenry E, O'Neill F, et al. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed 2007;92:F454-8 (Pubitemid 350044002)
114. Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006;49:484-92 (Pubitemid 44511100)
115. Ganesan K, Harigopal S, Neal T, et al. Prophylactic oral nystatin for preterm babies under 33 weeks' gestation decreases fungal colonisation and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed 2009;94:F275-8
116. Aydemir C, Oguz SS, Dizdar EA, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F164-8
117. Isaacs D. Fungal prophylaxis in very low birth weight neonates: nystatin, fluconazole or nothing? Curr Opin Infect Dis 2008;21:246-50 (Pubitemid 351620378)
118. El Masry FA, Neal TJ, Subhedar NV. Risk factors for invasive fungal infection in neonates. Acta Paediatr 2002;91:198-202 (Pubitemid 34252529)
119. Leibovitz E, Iuster-Reicher A, Amitai M, et al. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis 1992;14:485-91